Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine

Infection and Immunity

Volumn 64, Issue 7, 1996, Pages 2745-2751

  Van Der Voort, Eileene Rouppe ^a,b   Van Der Ley, Peter ^a   Van Der Biezen, Jenny ^a   George, Stephen ^a   Tunnela, Outi ^c   Van Dijken, Harry ^a   Kuipers, Betsy ^a   Poolman, Jan ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MENINGOCOCCUS VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL MENINGITIS; BACTERIAL OUTER MEMBRANE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MEMBRANE VESICLE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

EID: 0030002662     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.7.2745-2751.1996     Document Type: Article

References (41)

1. Abdillahi, H., and J. T. Poolman. 1987. Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol. Lett. 48:367-371.
2. Abdillahi, H., and J. T. Poolman. 1988. Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA. Microb. Pathog. 4:27-32.
3. Bartoloni, A., F. Norelli, C. Ceccarini, R. Rappuoli, and P. Costantino. 1995. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM 197 via adipic acid ditiydrazide. Vaccine 13:463-470.
4. Bjune, G., E. A. Høiby, J. K. Grønnesby, O. Arnesen, J. H. Frederiksen, A. Halstensen el al. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
5. Butcher, S., M. Sarvas, and K. Rnneberg-Nyman. 1991. Class 3 porin protein of Neisseria meningitidis: cloning and sequencing of the gene. Gene 105:125-128.
6. Butcher, S. J., P. J. Omar, M. Sarvas, and K. Runeberg-Nyman. 1991. Sequence comparisons of class 1 genes from Neisseria meningitidis and a folding model of the class 1 protein. Neisseriae 1990:193-198.
7. Cassio de Moraes, J., B. A. Perkins, M. C. C. Camargo, N. T. Rosetto Hidaldo, H. Aparecida Barbosa, C. Tavares Sacchi, V. L. Gattas, B. D. Plikaytis, and C. V. Broome. 1992. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340:1074-1078.
8. Claassen, I., J. Meylis, P. van der Ley, C. Peelers, H. Brims, J. Robert, D. Borsboom, A. van der Ark, I. van Straaten, P. Roholl, B. Kuipers, and J. Poolman. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine, in press.
9. Davies, R. L., R. A. Wall, and S. P. Borriello. 1990. Comparison of methods for the analysis of outer membrane antigens of Neisseria meningitidis by Western blotting. J. Immunol. Methods 134:215-225.
10. Finne, J., D. Bitter-Suerman, C. Goridis, and U. Finne. 1987. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J. Immunol. 138:4402-4407.
11. Frasch, C. E. 1989. Vaccines for prevention of meningococcal disease. Clin. Microbiol. Rev. 2:S134-S138.
12. Frasch, C. E. 1985. Status of a group B Neisseria meningitidis vaccine. Eur. J. Clin. Microbiol. 4:533-536.
13. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
14. Goodman, S. D., and J. J. Scocca. 1991. Factors influencing the specific interaction of Neisseria gonorrhoeae with transforming DNA. J. Bacteriol. 173:5921-5923.
15. Høiby, E. A., E. Rosenqvist, L. O. Fnøholm, G. Bjune, B. Feiring, H. Nøklehy, and E. Rønnild. 1991. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Annals 14:147-156.
16. Holten, E. 1979. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J. Clin. Microbiol. 9:186-188.
17. 16a.Käyhty, H., et al. Unpublished data.
18. 16b.Kuipers, A. J., and P. Hoogerhout. Unpublished data.
19. McGuinness, B., A. K. Barlow, I. N. Clarke, J. E. Farley, A. Anilionis, J. T. Poolman, and J. E. Heckels. 1990. Deduced amino acid analysis of class 1 protein (PorA) from three strains of Neisseria meningitidis: synthetic peptides define the epitopes responsible for serosubtype specificity. J. Exp. Med. 171:1871-1882.
20. McGuinness, B. T., I. N. Clarke, P. R. Lambden, A. K. Barlow, J. T. Poolman, D. M. Jones, and J. Heckels. 1991. Point mutation in meningococcal porA gene associated with increased endemic disease. Lancet 337:514-517.
21. Mead, D. A., and B. Kemper. 1988. Chimeric single-stranded DNA phageplasmid cloning vectors, p. 85-102. In R. L. Rodriguez and D. T. Denhardt (ed.), Vectors: a survey of molecular cloning vectors and their uses. Butter-worths, Boston.
22. Monod, M., C. Denoya, and C. Dubnau. 1986. Sequence and properties of p1M13. a macrolide-lincosamide-streptogramin B resistance plasmid from Bacillus subtilis. J. Bacteriol. 167:138-147.
23. Munkley, A., C. R. Tinsley, M. Virji, and J. E. Heckels. 1991. Blocking of bactericidal killing of Neisseria meningitidis antibodies directed against class 4 outer membrane protein. Microb. Pathog. 11:447-452.
24. Peeters, C. C. A. M., H. C. Rümke, L. C. Sundermann, E. M. Rouppe van der Voort, J. Meulenbelt, M. Schuller, A. J. Kuipers, P. van der Ley, and J. T. Poolman. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine, in press.
25. Peltola, H. 1984. Meningococcal disease: still with us. Rev. Infect. Dis. 5:71-91.
26. Poolman, J. T. 1995. Development of a meningococcal vaccine (Rev). Infect. Ag. and Dis. 4:13-28.
27. Poolman, J. T., F. B. Wientjes, C. T. P. Hopman, and H. C. Zanen. 1985. Influence of the length of the lipopolysaccharide molecules on the surface exposure of class 1 and 2 outer membrane proteins of Neisseria meningitidis 2996 (B:2b:P1.2), p. 562-570. In G. K. Schoolnik, G. F. Brooks, S. Falkow, C. E. Frasch, J. S. Knapp, J. A. McCutchan, and S. A. Morse (ed.), The pathogenic neisseriae. American Society for Microbiology, Washington, D.C.
28. Rosenqvist, E., E. A. Høiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Rønnild. G. Bjune. and H. Nøkleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
29. Rosenqvist, E., E. A. Høiby, E. Wedege, D. A. Caugant, L. O. Frohølm, B. T. McGuinness, J. Brooks, P. R. Lambden, and J. E. Heckels. 1993. A new variant of serosubtype PI.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine. Microb. Pathog. 15:197-205.
30. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
31. Saukkonen, K, H. Abdillahi, J. T. Poolman, and M. Leinonen. 1987. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B15:P1.16 in an infant rat infection model: new prospects for vaccine development. Microb. Pathog. 3:261-267.
32. Saukkonen, K.. M. Leinonen, H. Abdillahi, and J. T. Poolman. 1989. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7:325-328.
33. Scholten, R. J. P. M., H. A. Bijlmer, J. T. Poolman, A. J. Kuipers, D. A. Caugant, L. van Alphen, J. Dankert, and H. A. Valkenburg. 1993. Meningococcal disease in The Netherlands, 1958-1990. Steady increase of the incidence rate since 1982 partially caused by new serotypes and subtypes of Neisseria meningitidis. J. Clin. Infect. Dis. 16:237-246.
34. Scholten, R. J. P. M., B. Kuipers, H. A. Valkenburg, J. Dankert, W. D. Zollinger, and J. T. Poolman. 1994. Lipooligosaccharide immunotyping of Neisseria meningitidis by a whole cell ELISA using monoclonal antibodies and association of immunotype with serogroup, serotype and subtype. J. Med. Microbiol. 41:236-243.
35. Suker, J., I. M. Feavers, M. Achtman, G. Morelli, J.-F. Wang, and M. C. J. Maiden. 1994. The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation. Mol. Microbiol. 12:253-265.
36. Tommassen, J., P. Vermeij, M. Struyvé, R. Benz, and J. T. Poolman. 1990. Isolation of Neisseria meningitidis mutants deficient in class 1 (PorA) and class 3 (PorB) outer membrane proteins. Infect. Immun. 58:1355-1359.
37. van der Ley, P. A., J. E. Heckels, M. Virji, P. Hoogerhout, and J. T. Poolman. 1991. Topology of outer membrane porins in pathogenic Neisseria spp. Infect. Immun. 59:2963-2971.
38. van der Ley, P. A., and J. T. Poolman. 1992. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect. Immun. 60:3156-3161.
39. van der Ley, P. A., J. van der Biezen, P. Hohenstein, C. Peeters, and J. T. Poolman. 1993. Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningiiidis. Infect. Immun. 61:4217-4224.
40. van der Ley, P. A., J. van der Biezen, and J. T. Poolman. 1995. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13:401-407.
41. Wedege, E., R. Dalseg, D. A. Caugant, J. T. Poolman, and L. O. Frøholm. 1993. Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins. J. Med. Microbiol. 38:23-28.